Advanced search
Start date
Betweenand

Microbiota and fecal fermentation products of dogs with inflammatory bowel disease supplemented with beta-glucans

Grant number: 18/04574-5
Support type:Scholarships in Brazil - Master
Effective date (Start): June 01, 2018
Effective date (End): June 30, 2020
Field of knowledge:Agronomical Sciences - Veterinary Medicine - Animal Clinics and Surgery
Cooperation agreement: Coordination of Improvement of Higher Education Personnel (CAPES)
Principal researcher:Márcio Antonio Brunetto
Grantee:Andressa Rodrigues Amaral
Home Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Inflammatory bowel disease (IBD) is considered to be the most common cause of gastrointestinal disease in dogs and the most important cause of vomiting and diarrhea in dogs and cats. Although its pathogenesis is not fully understood and its etiology is multifactorial, there is a consensus in the literature about the existence of an aberrant immune reaction to microorganisms residing in the gastrointestinal tract in the genetically predisposed individual, associated with dysbiosis and consequent alteration in the concentration of fermentation of fermentation products. Prebiotics are non-starch polysaccharides resistant to the enzymatic digestion of monogastric animals that reach the large intestine capable of serving as a substrate for the growth and fermentation of beneficial bacteria, to the detriment of pathogens. The immunomodulatory effects performed through this selective fermentation have interesting therapeutic potential in patients with IBD, which are widely discussed in the human literature, although is poorly discussed in veterinary literature. Thus, the present study aims to evaluate the effects of ²-glucan supplementation on the faecal microbiota of dogs with IBD identified and quantified by the latest generation genetic sequencing and the concentration of fecal fermentation products. To do this, a minimum of twelve dogs with controlled stage IBD will be selected to form two experimental groups: A - supplemented with 0.1% ² - glucans and B - placebo, so that both will receive the same hydrolyzed diet associated or not to the prebiotic, during 60 days. In addition, routine blood chemistry and biochemical tests associated with serum folate and cobalamin dosage will be performed and, for the purpose of monitoring clinical signs, a canine enteropathy severity score specifically designed for this purpose will be applied. The results obtained will be analyzed using the Statistical Analysis System (SAS Institute Inc., 2004) and according to the distribution of the data, parametric or non-parametric statistical tests will be used. (AU)